This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.
By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
70 data tables and 50 additional tables
Analysis of the global market for oncology pharmaceuticals (cancer drugs)
Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
A Porter’s Five Forces model, and global supply chain and PESTLE analyses
An analysis of the key products on the market and promising new pipeline molecules or drugs under development
A look at the recent patent grants
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
Analysis of the industry structure, including companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.
Companies Mentioned
ABBVIE INC. AMGEN INC. ASTRAZENECA BRISTOL-MYERS SQUIBB CO. F. HOFFMANN-LA ROCHE LTD. JOHNSON & JOHNSON SERVICES INC. LILLY MERCK & CO. INC. NOVARTIS AG PFIZER INC. SANOFI TAKEDA PHARMACEUTICAL CO. LTD.
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Supply Chain Analysis
Research and Development
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Addressing Challenges in the Pharmaceutical Supply Chain
Costs
Regulations
Safety and Security
Porter’s Five Forces Analysis in the Oncology Market